Gill Saar, Wolf Max, Prince H Miles, Januszewicz Henry, Ritchie David, Hicks Rodney J, Seymour John F
Division of Haematology and Medical Oncology, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia.
Clin Lymphoma Myeloma. 2008 Jun;8(3):159-65. doi: 10.3816/CLM.2008.n.019.
Positron emission tomography (PET) is an important imaging modality in the staging and response assessment of patients with lymphoma, but data on its specific use in mantle cell lymphoma (MCL) are lacking.
The records of 28 patients with MCL who had a total of 123 [18F]fluorodeoxyglucose (FDG) PET scans between March 1999 and November 2005 were reviewed. Nine patients had staging scans. The other scans were performed for response assessment or relapse surveillance.
FDG-PET sensitivity was 100% for nodal disease in the 9 patients studied at baseline. Positron emission tomography scans performed for response assessment were concordant with conventional imaging in 47% and discordant in 53% of cases. Positron emission tomography scanning led to earlier diagnosis of relapse in 1 of 17 patients but produced a high rate of false-negative findings in the evaluation of gastrointestinal involvement.
FDG-PET appears to be a sensitive modality for staging and for response assessment in MCL but was not found to be useful in relapse surveillance or in the evaluation of gastrointestinal disease.
正电子发射断层扫描（PET）是淋巴瘤患者分期和疗效评估中的一种重要成像方式，但关于其在套细胞淋巴瘤（MCL）中的具体应用数据尚缺乏。
回顾了1999年3月至2005年11月期间28例MCL患者的记录，这些患者共进行了123次[18F]氟脱氧葡萄糖（FDG）PET扫描。9例患者进行了分期扫描。其他扫描用于疗效评估或复发监测。
在9例基线研究的患者中，FDG-PET对淋巴结疾病的敏感性为100%。用于疗效评估的PET扫描在47%的病例中与传统成像结果一致，在53%的病例中不一致。PET扫描使17例患者中的1例复发得到了更早诊断，但在评估胃肠道受累情况时产生了较高的假阴性率。
FDG-PET似乎是MCL分期和疗效评估的一种敏感方式，但在复发监测或胃肠道疾病评估中未发现有用。
